Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Springbok Analytics
Deal Size : Undisclosed
Deal Type : Partnership
Epicrispr and Springbok Partner to Integrate AI Muscle Analysis in FSHD Study
Details : The partnership aims to advance the clinical development of EPI-321, which is being evaluated in ther early-stage clinical trial studies for the treatment of FSHD.
Product Name : EPI-321
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 23, 2025
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Springbok Analytics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epicrispr Biotechnologies gets FDA IND Clearance for EPI-321 in FSHD
Details : EPI-321, a first-in-class epigenetic therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
Product Name : EPI-321
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2025
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Ally Bridge Group
Deal Size : $68.0 million
Deal Type : Series B Financing
Epicrispr Secures $68M Series B to Advance FSHD Epigenetic Therapy Trial
Details : The financing aims to fund the clinical development of lead program, EPI-321. It is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.
Product Name : EPI-321
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 26, 2025
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Ally Bridge Group
Deal Size : $68.0 million
Deal Type : Series B Financing